{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:05:55Z","timestamp":1777417555579,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","award":["18JCZDJC32600"],"award-info":[{"award-number":["18JCZDJC32600"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602026"],"award-info":[{"award-number":["81602026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"863 plans sub-topics","award":["2015AA021107"],"award-info":[{"award-number":["2015AA021107"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian cancer is the most fatal gynecologic malignancy worldwide due to its vagueness, delay in diagnosis, recurrence, and drug resistance. Therefore, a new type of ovarian cancer treatment prediction biomarker is urgently needed to supplement existing tools. A total of 230 people participated in this study. Out of this figure, 100 participants were patients who underwent an ovarian tumor operation, another 100 participants were ovarian benign patients, and the remaining 30 participants were healthy women. Cancer (experimental) group were 100 patients who underwent ovarian tumor operation, while the control groups were 130 participants consisting of 100 ovarian benign patients and 30 healthy women. Levels of SAA, carbohydrate antigen-125 (CA-125), and human epididymis protein 4 (HE4) were assessed using standard laboratory protocols. A total of 5 ovarian cancer tissues and paracancerous tissues were collected and then stored at \u2212\u200980\u2009\u00b0C until the qRT-PCR assay was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The ROC curve of SAA concentration in ovarian cancer was plotted to obtain the area under the curve AUC\u2009=\u20090.889, the cut-off value 17.05\u2009mg\/L, the sensitivity 78.4% and specificity 86.5%. Compared with pretreatment, the level of serum SAA decreased significantly after treatment. The results revealed that there was a significant correlation between the level of serum SAA and advanced FIGO stage, histology subtype, lymphatic invasion, and distant metastasis (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.003,0.002,0.000 and 0.001). The quantitative Reverse transcription polymerase chain reaction (qRT-PCR) assay revealed that the Messenger RNA (mRNA) of SAA-1 and SAA-4 was much higher in cancer tissues than in adjacent tissues, and MMPs was up-regulation including MMP-1, MMP-9 and MMP- 12 in OVCAR-3 cell stimulated by SAA. The transwell assay revealed that SAA could promote OVCAR-3 cell migration. Moreover, SAA can regulate EMT markers and promote AKT pathway activation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In summary, our results demonstrated that SAA may be a potential diagnosis and treatment prediction biomarker. The SAA promotes OVCAR-3 cell migration by regulating MMPs and EMT which may correlate with AKT pathway activation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-020-00669-w","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T18:02:42Z","timestamp":1591725762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Serum amyloid a, a potential biomarker both in serum and tissue, correlates with ovarian cancer progression"],"prefix":"10.1186","volume":"13","author":[{"given":"Ze","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongwang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3689-3843","authenticated-orcid":false,"given":"Li","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"key":"669_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 5","key":"669_CR2","doi-asserted-by":"publisher","first-page":"v31","DOI":"10.1093\/annonc\/mdq205","volume":"21","author":"N Reed","year":"2010","unstructured":"Reed N, Millan D, Verheijen R, Castiglione M. Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v31\u20136.","journal-title":"Ann Oncol"},{"key":"669_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1535-6108(04)00002-9","volume":"5","author":"RF Ozols","year":"2004","unstructured":"Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC. Focus on epithelial ovarian cancer. Cancer Cell. 2004;5:19\u201324.","journal-title":"Cancer Cell"},{"key":"669_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","volume":"13","author":"S Narod","year":"2016","unstructured":"Narod S. Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol. 2016;13:255\u201361.","journal-title":"Nat Rev Clin Oncol"},{"key":"669_CR5","first-page":"2837","volume":"92","author":"C van Haaften-Day","year":"2001","unstructured":"van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RJ, Hacker NF. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer-Am Cancer Soc. 2001;92:2837\u201344.","journal-title":"Cancer-Am Cancer Soc"},{"key":"669_CR6","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1097\/IGC.0000000000000804","volume":"26","author":"F Dayyani","year":"2016","unstructured":"Dayyani F, Uhlig S, Colson B, Simon K, Rolny V, Morgenstern D, Schlumbrecht M. Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in connection with ovarian Cancer: a meta-analysis. Int J Gynecol Cancer. 2016;26:1586\u201393.","journal-title":"Int J Gynecol Cancer"},{"key":"669_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2012.09.034","volume":"128","author":"KK Chan","year":"2013","unstructured":"Chan KK, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Sumpaico WW. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecol Oncol. 2013;128:239\u201344.","journal-title":"Gynecol Oncol"},{"key":"669_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","volume":"104","author":"T Van Gorp","year":"2011","unstructured":"Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, De Moor B, Vergote I. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011;104:863\u201370.","journal-title":"Br J Cancer"},{"key":"669_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/prca.200600229","volume":"1","author":"SA Moshkovskii","year":"2007","unstructured":"Moshkovskii SA, Vlasova MA, Pyatnitskiy MA, Tikhonova OV, Safarova MR, Makarov OV, Archakov AI. Acute phase serum amyloid a in ovarian cancer as an important component of proteome diagnostic profiling. Proteomics Clin Appl. 2007;1:107\u201317.","journal-title":"Proteomics Clin Appl"},{"key":"669_CR10","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1292\/jvms.70.1247","volume":"70","author":"T Tamamoto","year":"2008","unstructured":"Tamamoto T, Ohno K, Ohmi A, Goto-Koshino Y, Tsujimoto H. Verification of measurement of the feline serum amyloid a (SAA) concentration by human SAA turbidimetric immunoassay and its clinical application. J Vet Med Sci. 2008;70:1247\u201352.","journal-title":"J Vet Med Sci"},{"key":"669_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0076-6879(88)63037-0","volume":"163","author":"I Kushner","year":"1988","unstructured":"Kushner I. The acute phase response: an overview. Methods Enzymol. 1988;163:373\u201383.","journal-title":"Methods Enzymol"},{"key":"669_CR12","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.2174\/0929867323666160418114600","volume":"23","author":"M De Buck","year":"2016","unstructured":"De Buck M, Gouwy M, Wang JM, Van Snick J, Opdenakker G, Struyf S, Van Damme J. Structure and expression of different serum amyloid a (SAA) variants and their concentration-dependent functions during host insults. Curr Med Chem. 2016;23:1725\u201355.","journal-title":"Curr Med Chem"},{"key":"669_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1365-2362.1996.159291.x","volume":"26","author":"E Malle","year":"1996","unstructured":"Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Investig. 1996;26:427\u201335.","journal-title":"Eur J Clin Investig"},{"key":"669_CR14","doi-asserted-by":"crossref","unstructured":"Armstrong H, Bording-Jorgensen M, Dijk S, Wine E. The complex interplay between chronic inflammation, the microbiome, and Cancer: understanding disease progression and what we can do to prevent it. Cancers (Basel). 2018;10.","DOI":"10.3390\/cancers10030083"},{"key":"669_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00018-008-8321-x","volume":"66","author":"E Malle","year":"2009","unstructured":"Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid a: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci. 2009;66:9\u201326.","journal-title":"Cell Mol Life Sci"},{"key":"669_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of Cancer: the next generation. CELL. 2011;144:646\u201374.","journal-title":"CELL."},{"key":"669_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1186\/s12885-016-2882-0","volume":"16","author":"R Biaoxue","year":"2016","unstructured":"Biaoxue R, Hua L, Wenlong G, Shuanying Y. Increased serum amyloid a as potential diagnostic marker for lung cancer: a meta-analysis based on nine studies. BMC Cancer. 2016;16:836.","journal-title":"BMC Cancer"},{"key":"669_CR18","doi-asserted-by":"publisher","first-page":"35843","DOI":"10.18632\/oncotarget.8561","volume":"7","author":"M Yang","year":"2016","unstructured":"Yang M, Liu F, Higuchi K, Sawashita J, Fu X, Zhang L, Zhang L, Fu L, Tong Z, Higuchi K. Serum amyloid a expression in the breast cancer tissue is associated with poor prognosis. Oncotarget. 2016;7:35843\u201352.","journal-title":"Oncotarget."},{"key":"669_CR19","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1292\/jvms.14-0108","volume":"76","author":"T Tamamoto","year":"2014","unstructured":"Tamamoto T, Ohno K, Goto-Koshino Y, Tsujimoto H. Serum amyloid a promotes invasion of feline mammary carcinoma cells. J Vet Med Sci. 2014;76:1183\u20138.","journal-title":"J Vet Med Sci"},{"key":"669_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1746-1596-9-16","volume":"9","author":"Y Ren","year":"2014","unstructured":"Ren Y, Wang H, Lu D, Xie X, Chen X, Peng J, Hu Q, Shi G, Liu S. Expression of serum amyloid a in uterine cervical cancer. Diagn Pathol. 2014;9:16.","journal-title":"Diagn Pathol"},{"key":"669_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/sj.bjc.6605720","volume":"103","author":"SL Wood","year":"2010","unstructured":"Wood SL, Rogers M, Cairns DA, Paul A, Thompson D, Vasudev NS, Selby PJ, Banks RE. Association of serum amyloid a protein and peptide fragments with prognosis in renal cancer. Br J Cancer. 2010;103:101\u201311.","journal-title":"Br J Cancer"},{"key":"669_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1245\/s10434-006-9091-z","volume":"14","author":"DC Chan","year":"2007","unstructured":"Chan DC, Chen CJ, Chu HC, Chang WK, Yu JC, Chen YJ, Wen LL, Huang SC, Ku CH, Liu YC, Chen JH. Evaluation of serum amyloid a as a biomarker for gastric cancer. Ann Surg Oncol. 2007;14:84\u201393.","journal-title":"Ann Surg Oncol"},{"key":"669_CR23","first-page":"843","volume":"116","author":"E Cocco","year":"2010","unstructured":"Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid a: a novel biomarker for endometrial cancer. Cancer-Am Cancer Soc. 2010;116:843\u201351.","journal-title":"Cancer-Am Cancer Soc"},{"issue":"1","key":"669_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1746-1596-9-16","volume":"9","author":"REN Yanjie","year":"2014","unstructured":"Yanjie REN, He WANG, Donghao LU, et al. Expression of serum amyloid a inuterine cervical cancer. Diagn Pathol. 2014;9(1):16.","journal-title":"Diagn Pathol"},{"key":"669_CR25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"669_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267\u201373.","journal-title":"Nat Genet"},{"key":"669_CR27","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1369\/jhc.2010.956821","volume":"58","author":"S Urieli-Shoval","year":"2010","unstructured":"Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, Galinsky D, Linke RP, Ariel I, Levin M, Ben-Shachar I, Prus D. Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J Histochem Cytochem. 2010;58:1015\u201323.","journal-title":"J Histochem Cytochem"},{"key":"669_CR28","first-page":"617","volume":"10","author":"F Arvelo","year":"2016","unstructured":"Arvelo F, Sojo F, Cotte C. Tumour progression and metastasis. Ecancermedicalscience. 2016;10:617.","journal-title":"Ecancermedicalscience."},{"key":"669_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.canlet.2013.01.013","volume":"332","author":"GH Ha","year":"2013","unstructured":"Ha GH, Park JS, Breuer EK. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K\/Akt and ERK signaling pathways. Cancer Lett. 2013;332:63\u201373.","journal-title":"Cancer Lett"},{"key":"669_CR30","doi-asserted-by":"publisher","unstructured":"Wang JY, Zheng YZ, Yang J, Lin YH, Dai SQ, Zhang G, Liu WL. Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma. BMC Cancer. 2012; https:\/\/doi.org\/10.1186\/1471-2407-12.365.","DOI":"10.1186\/1471-2407-12.365"},{"key":"669_CR31","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.20301","volume":"50","author":"R O'Hara","year":"2004","unstructured":"O'Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Local expression of the serum amyloid a and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum. 2004;50:1788\u201399.","journal-title":"Arthritis Rheum"},{"key":"669_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.vetimm.2017.03.002","volume":"187","author":"T Tamamoto","year":"2017","unstructured":"Tamamoto T, Ohno K, Goto-Koshino Y, Tsujimoto H. Effects of serum amyloid a on matrix metalloproteinase-9 production in feline lymphoma-derived cell lines. Vet Immunol Immunopathol. 2017;187:10\u20133.","journal-title":"Vet Immunol Immunopathol"},{"key":"669_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/IJN.S148487","volume":"13","author":"G Deng","year":"2018","unstructured":"Deng G, Zhou F, Wu Z, Zhang F, Niu K, Kang Y, Liu X, Wang Q, Wang Y, Wang Q. Inhibition of cancer cell migration with CuS@ mSiO2-PEG nanoparticles by repressing MMP-2\/MMP-9 expression. Int J Nanomedicine. 2018;13:103\u201316.","journal-title":"Int J Nanomedicine"},{"key":"669_CR34","doi-asserted-by":"publisher","first-page":"39230","DOI":"10.18632\/oncotarget.16837","volume":"8","author":"J An","year":"2017","unstructured":"An J, Xue Y, Long M, Zhang G, Zhang J, Su H. Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells. Oncotarget. 2017;8:39230\u201340.","journal-title":"Oncotarget."},{"key":"669_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000139134","volume":"46","author":"Y Zhao","year":"2009","unstructured":"Zhao Y, Zhou S, Heng CK. Celecoxib inhibits serum amyloid a-induced matrix metalloproteinase-10 expression in human endothelial cells. J Vasc Res. 2009;46:64\u201372.","journal-title":"J Vasc Res"},{"key":"669_CR36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.bbrc.2005.03.069","volume":"330","author":"HY Lee","year":"2005","unstructured":"Lee HY, Kim MK, Park KS, Bae YH, Yun J, Park JI, Kwak JY, Bae YS. Serum amyloid a stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys Res Commun. 2005;330:989\u201398.","journal-title":"Biochem Biophys Res Commun"},{"key":"669_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.matbio.2015.01.019","volume":"44-46","author":"G Shay","year":"2015","unstructured":"Shay G, Lynch CC, Fingleton B. Moving targets: emerging roles for MMPs in cancer progression and metastasis. Matrix Biol. 2015;44-46:200\u20136.","journal-title":"Matrix Biol"},{"key":"669_CR38","doi-asserted-by":"publisher","first-page":"6253","DOI":"10.1128\/MCB.14.9.6253","volume":"14","author":"SY Lu","year":"1994","unstructured":"Lu SY, Rodriguez M, Liao WS. YY1 represses rat serum amyloid A1 gene transcription and is antagonized by NF-kappa B during acute-phase response. Mol Cell Biol. 1994;14:6253\u201363.","journal-title":"Mol Cell Biol"},{"key":"669_CR39","doi-asserted-by":"publisher","first-page":"17770","DOI":"10.1074\/jbc.M010307200","volume":"276","author":"Y Ren","year":"2001","unstructured":"Ren Y, Liao WS. Transcription factor AP-2 functions as a repressor that contributes to the liver-specific expression of serum amyloid A1 gene. J Biol Chem. 2001;276:17770\u20138.","journal-title":"J Biol Chem"},{"key":"669_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.molimm.2014.02.011","volume":"59","author":"KD Nguyen","year":"2014","unstructured":"Nguyen KD, Macaubas C, Truong P, Wang N, Hou T, Yoon T, Mellins ED. Serum amyloid a induces mitogenic signals in regulatory T cells via monocyte activation. Mol Immunol. 2014;59:172\u20139.","journal-title":"Mol Immunol"},{"issue":"7747","key":"669_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41586-019-1004-y","volume":"567","author":"JW Lee","year":"2019","unstructured":"Lee JW, Stone ML, Porrett PM, Thomas SK, et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature. 2019;567(7747):249\u201352.","journal-title":"Nature."},{"key":"669_CR42","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1365-2141.2004.05121.x","volume":"126","author":"PL Tazzari","year":"2004","unstructured":"Tazzari PL, Cappellini A, Grafone T, Mantovani I, Ricci F, Billi AM, Ottaviani E, Conte R, Martinelli G, Martelli AM. Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry. Br J Haematol. 2004;126:675\u201381.","journal-title":"Br J Haematol"},{"key":"669_CR43","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1074\/jbc.M709585200","volume":"283","author":"YC Kuo","year":"2008","unstructured":"Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY, Chiang CW. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem. 2008;283:1882\u201392.","journal-title":"J Biol Chem"},{"key":"669_CR44","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.1074\/jbc.M110.179101","volume":"286","author":"JL Coloff","year":"2011","unstructured":"Coloff JL, Mason EF, Altman BJ, Gerriets VA, Liu T, Nichols AN, Zhao Y, Wofford JA, Jacobs SR, Ilkayeva O, Garrison SP, Zambetti GP, Rathmell JC. Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. J Biol Chem. 2011;286:5921\u201333.","journal-title":"J Biol Chem"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00669-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-020-00669-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00669-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T19:35:15Z","timestamp":1623180915000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-020-00669-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["669"],"URL":"https:\/\/doi.org\/10.1186\/s13048-020-00669-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.19755\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.19755\/v2","asserted-by":"object"}]},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"21 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was conducted in accordance with the Declaration of Helsinki. Study has been granted Tianjin Medical University Cancer Institute and Hospital ethics committee approval prior to commencing. All participants have informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}